Autoimmune Diseases
Conference Coverage
Rituximab is dramatically effective in IgG4-related disease
SNOWMASS, COLO. – If glucocorticoids do not bring patients with immunoglobulin G4-related disease into long-term sustained remission, B cell...
Conference Coverage
IgG4-related disease can strike any organ system
SNOWMASS, COLO. – John H. Stone, MD, describes how, within the past decade, substantial progress has been made in identifying immunoglobulin G4-...
From the Journals
Intermediate nature of ‘incomplete’ lupus shown in large study
People with incomplete lupus erythematosus exhibit nearly as many disease-related symptoms as do those with systemic lupus erythematosus and often...
News
VIDEO: Pattern recognition provides clues to rheumatologic diagnoses
Several patterns can provide clues to diagnoses of rheumatologic diseases, according to Daniel E. Furst, MD, professor of rheumatology, University...
From the Journals
New histopathologic marker may aid dermatomyositis diagnosis
The detection of sarcoplasmic myxovirus resistance A expression in immunohistochemical analysis of muscle biopsy in patients suspected of having...
Conference Coverage
VIDEO: Despite toxicities, ibrutinib is beneficial for treatment-resistant graft-vs.-host disease
SAN DIEGO – An oral regimen of 420 mg ibrutinib achieved complete response in one-third of allogeneic stem cell recipients with chronic graft-vs.-...
From the Journals
Nailfold analysis can predict cardiopulmonary complications in systemic sclerosis
Nailfold videocapillaroscopy can help to predict which patients with systemic sclerosis may develop serious cardiopulmonary complications,...
Conference Coverage
Lupus patients may be shortchanged on lipid management
WASHINGTON
Conference Coverage
Prenatal exposure to hydroxychloroquine cuts risk of neonatal cutaneous lupus
WASHINGTON - Prenatal hydroxychloroquine reduces the risk of cutaneous neonatal lupus by 60% among the infants of women with a systemic autoimmune...
Conference Coverage
Mycophenolate puts lupus patients in remission faster than azathioprine
WASHINGTON
Conference Coverage
ADDRESS II study: Atacicept shows promise for SLE
WASHINGTON – The recombinant fusion protein atacicept, which targets B-cell stimulating factors BLyS and APRIL, had a favorable safety profile and...